VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Agarwal on Toxicities With Checkpoint Inhibitors in RCC

Neeraj Agarwal, MD
Published: Friday, Jan 20, 2017



Neeraj Agarwal, associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses some of the adverse events (AEs) associated with checkpoint inhibitors for the treatment of patients with renal cell carcinoma (RCC).

Some of the most common side effects related to immunotherapy agents are fatigue, thyroid disfunction, renal insufficiency, and gastrointestinal side effects such has diarrhea. However, this can be severe and lead to colitis, Agarwal explains.

Agarwal says that nearly every organ can be negatively affected by these therapies. In a New England Journal of Medicine article, researchers documented cases of myocarditis with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with melanoma.


Neeraj Agarwal, associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses some of the adverse events (AEs) associated with checkpoint inhibitors for the treatment of patients with renal cell carcinoma (RCC).

Some of the most common side effects related to immunotherapy agents are fatigue, thyroid disfunction, renal insufficiency, and gastrointestinal side effects such has diarrhea. However, this can be severe and lead to colitis, Agarwal explains.

Agarwal says that nearly every organ can be negatively affected by these therapies. In a New England Journal of Medicine article, researchers documented cases of myocarditis with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with melanoma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x